IDEAYA's RTOR pathway choice sets a sequencing template for oncology NDAs

FDA's agreement to review IDEAYA Biosciences' darovasertib NDA under the Real-Time Oncology Review program offers regulatory affairs teams a live case study in accelerated submission sequencing, one that begins with a first pre-submission in May 2026 and targets full NDA filing in the second half of the year.

IDEAYA initiates RTOR process for darovasertib NDA in uveal melanoma

The FDA's Oncology Center of Excellence (OCE) has agreed to review IDEAYA's planned new drug application for darovasertib under the Real-Time Oncology Review (RTOR) program. The NDA is intended to support potential U.S. accelerated approval in first-line HLA*A2-negative metastatic uveal melanoma (mUM), a rare indication with limited approved systemic options.

The submission follows positive topline data from the Phase 2/3 OptimUM-02 registrational trial, reported April 13, 2026. The darovasertib and crizotinib combination met its primary endpoint, reducing the risk of disease progression by 58% versus investigator choice of therapy (hazard ratio 0.42; 95% CI: 0.30, 0.59; p<0.0001). Median progression-free survival by blinded independent central review was 6.9 months versus 3.1 months in the control arm. Overall response rate reached 37.1% in the combination arm versus 5.8% in the control arm (p<0.0001), with a median duration of response of 6.8 months. Overall survival data were not yet mature at the time of the primary analysis.

Complete data from OptimUM-02 will be presented in a late-breaking oral session at the 2026 American Society of Clinical Oncology (ASCO) meeting in Chicago, with manuscript submission planned for the second half of 2026.

The regulatory sequencing read for oncology NDA teams

RTOR allows rolling submission of completed NDA modules before the full application is formally filed, a sequencing advantage that compresses FDA review time when data packages are ready in stages. For regulatory affairs leads managing oncology programs, IDEAYA's approach illustrates how a pre-submission strategy can be initiated within weeks of topline data readout: the first pre-submission is targeted for May 2026, roughly three to four weeks after the April 13 data announcement.

The practical implication for CMC and regulatory teams is that RTOR readiness requires manufacturing, nonclinical, and clinical modules to be submission-ready on a rolling basis rather than assembled in a single filing sprint. Programs that have not pre-positioned CMC documentation, including process validation packages and stability data aligned to ICH Q8/Q9/Q10 expectations, may find the RTOR timeline difficult to exploit even when clinical data are strong.

Read against the accelerated approval framework under 21 CFR Part 314 Subpart H, the darovasertib filing will also require a confirmatory trial commitment. Overall survival data from OptimUM-02 were not yet mature at the primary analysis, which is a standard feature of accelerated approval submissions in oncology but one that post-marketing commitment planning teams should build into their regulatory timelines now.

Key milestones to track through H2 2026

Beyond the NDA filing, IDEAYA has flagged several pipeline readouts that regulatory and clinical operations teams at partnering or competing programs may want to track. Clinical data updates from the Phase 2 OptimUM-01 trial in HLA*A2-positive mUM and the Phase 2 OptimUM-09 neoadjuvant primary UM trial are both planned for the second half of 2026.

Separately, initiation of a registrational trial for IDE849, a DLL3-targeting topoisomerase I ADC, in DLL3-positive solid tumors is planned by year-end 2026. A Phase 1 combination cohort of IDE892 (PRMT5 inhibitor) with IDE397 (MAT2A inhibitor) in MTAP-deleted cancers is scheduled to begin mid-2026. These timelines, if met, will generate a dense data calendar in the back half of the year that intersects with the darovasertib NDA filing window.

IDEAYA reported approximately $973 million in cash, cash equivalents, and marketable securities as of March 31, 2026, with cash runway guidance unchanged through 2030, a financial position that supports the parallel execution of multiple late-stage regulatory and clinical programs without near-term financing pressure.

The first RTOR pre-submission in May 2026 will be the earliest measurable checkpoint for regulatory teams assessing how IDEAYA's submission sequencing holds against the H2 2026 NDA filing target.